Back

COMy 2022 - 8th World Congress on Controversies in Multiple Myeloma

May 12 - May 14, 2022 | ParisFrance

LARVOL is not affiliated with 8th World Congress on Controversies in Multiple Myeloma and all trademarks, logos, and brand names are property of their respective owners

Showing 11 abstracts linked to Trials

INSURE: A GLOBAL POOLED ANALYSIS (INSIGHT MM, UVEA-IXA, AND REMIX) OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH IXAZOMIB-LENALIDOMIDEDEXAMETHASONE (IRD) IN ROUTINE CLINICAL PRACTICE

CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) VERSUS PHYSICIAN’S CHOICE OF TREATMENT (PCT): A META-ANALYSIS IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)

ADDITION OF CARFILZOMIB AS A THIRD AGENT IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA: SWITCHING FROM DOUBLET TO TRIPLET

  • Poster